Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AllerVarx
- Development stage
- Unknown
- Lead developer
- NTC Pharma
- Administration
- Oral
01
Overview
AllerVarx, also known as Lertal in Europe, is a patented Natural Health Product developed by NTC s.r.l. and exclusively in-licensed by Innovus Pharma for the U.S. and Canadian markets. It is indicated for the alleviation of symptoms associated with allergic rhinitis.
- Brand names
- AllerVarxLertal
Beyond the preview
Go deeper on AllerVarx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllerVarx.